Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer - Concepedia

Concepedia

Publication | Open Access

Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer

DOI Full Paper Access

358

Citations

75

References

2006

Year

John Nemunaitis, Robert O. Dillman, Paul Schwarzenberger, Neil Senzer, Casey Cunningham, Jodi Cutler, Alex Tong, Padmasini Kumar, Beena O. Pappen, Cody Hamilton,

Journal of Clinical Oncology

Abstract

Belagenpumatucel-L is well tolerated, and the survival advantage justifies further phase III evaluation.

References

	Year	Citations

Page 1